Overview of the Components of Cardiac Metabolism

Elizabeth A. Hausner, Susan A. Elmore, and Xi Yang

United States Food and Drug Administration, Center for Drug Evaluation and Research, Silver Spring, Maryland (E.A.H., X.Y.); and National Toxicology Program, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina (S.A.E.)

Received January 30, 2019; accepted March 26, 2019

ABSTRACT

Metabolism in organs other than the liver and kidneys may play a significant role in how a specific organ responds to chemicals. The heart has metabolic capability for energy production and homeostasis. This homeostatic machinery can also process xenobiotics. Cardiac metabolism includes the expression of numerous organic anion transporters, organic cation transporters, organic carnitine (zwitterion) transporters, and ATP-binding cassette transporters. Expression and distribution of the transporters within the heart may vary, depending on the patient’s age, disease, endocrine status, and various other factors. Several cytochrome P450 (P450) enzyme classes have been identified within the heart. The P450 hydroxylases and epoxygenases within the heart produce hydroxyeicosatetraenoic acids and epoxyeicosatrienoic acids, metabolites of arachidonic acid, which are critical in regulating homeostatic processes of the heart. The susceptibility of the cardiac P450 system to induction and inhibition from exogenous materials is an area of expanding knowledge, as are the metabolic processes of glucuronidation and sulfation in the heart. The susceptibility of various transcription factors and signaling pathways of the heart to disruption by xenobiotics is not fully characterized but is an area with implications for disruption of normal postnatal development, as well as modulation of adult cardiac health. There are knowledge gaps in the timelines of physiologic maturation and deterioration of cardiac metabolism. Cross-species characterization of cardiac-specific metabolism is needed for nonclinical work of optimum translational value to predict possible adverse effects, identify sensitive developmental windows for the design and conduct of informative nonclinical and clinical studies, and explore the possibilities of organ-specific therapeutics.

Introduction

The extensive and expanding volume of information on the components of hepatic metabolism is now accompanied by a new perspective on extrahepatic drug metabolism. In addition to drug metabolism in the kidneys, lungs, and gastrointestinal tract, it is recognized that other organs, including the heart, have the capacity for xenobiotic metabolism, as well as the extensive processes involved in the endobiotic transformations necessary for homeostasis (Stegeaman et al., 1982; Wu et al., 1997; Gervasini et al., 2004; Pavek and Dvorak, 2008). Although this is a minor portion of overall systemic metabolism, there is potential for local drug metabolism to be an important factor in both desired pharmacology and unwanted cardiotoxicity. This factor is especially important when considering populations that may be more vulnerable to adverse drug effects, such as children or elderly patients.

This research was supported in part by the Intramural Research Program of the National Institutes of Health (NIH) National Institute of Environmental Health Sciences (NIEHS).

https://doi.org/10.1124/dmd.119.086611

ABBREVIATIONS: AA, arachidonic acid; ABC, ATP-binding cassette; AJ, adherens junction; AOX, aldehyde oxidase; Cx, connexin; EET, epoxyeicosatrienoic acid; GLUT, facilitative glucose transporter; HETE, hydroxyeicosatetraenoic acid; ID, intercalated disk; MRP, multidrug resistance protein; NAT, N-acetyltransferase; OAT, organic anion transporter; OATP, organic anion transporting polypeptide; OCT, organic cation transporter; OCTN, organic carnitine transporter; P450, cytochrome P450; PANX, pannexin; P-gp, P-glycoprotein; SGLT, sodium-glucose cotransporter; SULT, sulfotransferase; TJ, tight junction; ZO-1, zona occludens-1.
The same nexus of development that integrates signaling pathways from spatially separated organs primarily processes endogenous substances such as hormones, fatty acids, glucose, prostaglandins, and other substances for homeostasis. The receptors, transporters, sensors, and enzymes of metabolism may be developmentally regulated, and they may in turn help to coordinate postnatal development by their roles in communication between organ systems.

At any age, variability of expression and/or function of transporters and metabolic enzyme systems may contribute to observed variability of response to a therapeutic agent. Another important factor is the role of the heart in several endocrine axes. The heart demonstrates endocrine function in the regulation of blood pressure and volume involving distant communication with kidneys, adrenal glands, and vascular smooth muscle cells through the renin-angiotensin-aldosterone system, as well as cardiac-initiated signals from the natriuretic peptides and endogenous neural signals (Brownsey et al., 1997; McGrath et al., 2005; Ogawa and de Bold, 2014). Insulin and thyroid hormones have been indicated in the postnatal development of the heart, as well as having effects on enzymes, transporters, and protein expression throughout life (Krüger et al., 2008; Barreto-Chaves et al., 2010; Jonker and Louey, 2016; Ock et al., 2016). Many of the molecules involved in metabolism within the heart appear to work in concert with protein partners, a phenomenon that appears to create and maintain coordination within and between cells (Brownsey et al., 1997; Meens et al., 2015). The insulin receptor is one example of a coordination of signaling proteins, with the receptor producing a localized cardiac effect (Brownsey et al., 1997). Another example is the role of the thyroid in most aspects of cardiovascular function. Thyroid hormone effects are mediated directly by thyroid hormone receptors in the heart and indirectly via factors including the autonomic nervous system, the renin-angiotensin-aldosterone system, and renal function. The phosphorylation/activation of phosphoinositol 3-kinase, protein kinase B, and mammalian target of rapamycin are mediators of thyroid hormone involvement in cardiomyocyte protection, growth, and maturation, including developmental protein isoform shifts [reviewed in Kuzman et al. (2005), Kenessey and Ojamaa (2006), Krüger et al. (2008), Dillmann (2010), Chattergoon et al. (2012), and Grais and Sowers (2014)]. The multitude of proteins within the heart and the developmentally regulated shifts that occur throughout life make the morphologic status of the heart a component of the metabolic milieu.

In drug development, the biologic fate of a xenobiotic is determined by absorption, distribution, metabolism, and excretions, topics we address in this review based on the current literature findings. In addition to this paradigm, many factors need to be considered in choosing an animal species for nonclinical studies in cardiac physiology and pharmacology. The relevance of those results in guiding clinical studies or drug development depends on knowledge of the similarities and differences across species. Detailed understanding of cardiac metabolism offers the possibility of targeted, organ-specific therapy or, conversely, avoiding cardiac-specific toxicity, which includes both direct adverse effects of a therapeutic effect as well as indirect effects caused by disruption of metabolism needed for homeostasis or normal development. Thus, knowledge of cardiac metabolism has the potential to improve therapeutic safety for both children and adults. Finally, nonclinical studies conducted with a clear understanding of cardiac metabolism in different species will enhance the translational value of such work supporting the standards of the three Rs: reduce, refine, and replace. The focus of this manuscript is compilation of the current understanding of metabolism endogenous to the heart. Part of this endeavor includes identification of data gaps.
Developmentally regulated protein isoforms and the maturational state of gap junction complexes determine myocardial contractility.

Various signaling pathways, described in detail elsewhere and beyond the scope of this review, also contribute to the regulation of endothelial junction permeability. Modulators to permeability include lipopolysaccharide, thrombin, and vascular endothelial growth factor. The endothelial junctions AJ and TJ are also involved in cell growth, apoptosis, and gene expression (Vandebroucke et al., 2008; Yoon et al., 2014).

Passage across or into an endothelial cell includes a transcellular pathway (caveolea-mediated transcytosis or active transport) or the paracellular pathway of passive movement through the intercellular space between adjacent endothelial cells (e.g., lipopolysaccharide molecules traverse primarily by passive diffusion). The transcellular/caveolea pathway may require the involvement of receptors, pumps, or transport proteins, described as follows.

**Connexins.** In addition to endothelial cells, connexins (Cx) are components of the blood vessel wall. Cx40, found in both gap junctions and the blood vessel wall, are membrane proteins found throughout the body. Six Cx subunits can form a connexon, or hemichannel, in the plasma membrane of the cell. This connexon can then appose to the connexin of an adjacent cell to form a gap junction channel. In blood vessels, the connexins allow for intercellular communication between endothelial cells, smooth muscle cells, and myoendothelial coupling. Within the heart overall, connexons are primarily recognized for permitting cell-to-cell, nonspecific passage of ions (Makowski et al., 1984; de Wit and Griffith, 2010). Transgenic mice have been used for elucidation of the role of connexins in arrhythmias and conduction disorders (Verheule and Kaese, 2013). Recent work examines the role of connexins in disturbances of the cardiac electrical conduction system (Santa Cruz et al., 2015).

Several different Cxs have been identified to date in human, mouse, rat, dog, and rabbit hearts (Coppen et al., 1999, 2001). A recent addition to this list is Cx26 (Moscati et al., 2018). Cx40, Cx43, Cx44, and Cx45 are the primary signature proteins of gap junctions, endocardium, coronary vessels, and aorta, but they have not been identified in myocardial capillaries. Cx37 has been detected in endothelial cells (Gros and Jongma, 1996). Various studies have shown that the temporal and spatial expression of each protein, as well as abundance of each protein within the cardiac tissue, varies among species. Coppen et al. (1999) investigated the spatial expression pattern of Cx40, Cx43, and Cx45 in rabbits using dual-channel scanning confocal microscopy and determined that Cx40 and Cx45, but not Cx43, were expressed in the central SA node. Another investigation of immunolabeled Cx40, Cx43, and Cx45 in BALB/c mice, from embryonic day 12.5 to adult, determined that Cx45 is the earliest detectable connexin in the central conduction system and, in addition, is the only connexin expressed throughout the entire conduction system (Coppen et al., 2001). Another study found Cx43 to be the predominant Cx throughout the rat heart based on quantity, found on myocytes of both atria and ventricles (Van Kempen et al., 1996). This study also found that expression of Cx43 in the rat is uniform at birth and changes to punctate during the postnatal period. There is also some expression in fibroblasts and the electrical conduction system of humans (Purkinje fibers and intercalated discs), mice, and rats (Gourdie et al., 1993; Chen et al., 1994). Cx43 is also found in cardiomyocyte mitochondria of mouse, rat, pig, and human origin, possibly associated with cell death and survival (Boengler et al., 2005; Miro-Casas et al., 2009; Jovic et al., 2012; reviewed in Rodríguez-Sinovas et al. (2012)). An association between connexin 43 and myosin VI, one of the sarcomeric motor proteins, has been demonstrated in mice to be necessary for gap-junction maintenance of morphology and intercellular communication (Waxse et al., 2017).

In the rat, Cx40 has been reported in the atria before birth and is highly expressed in the ventricle early in development, declining to minimal or no ventricular expression in adulthood (Van Kempen et al., 1996), similar to that seen in humans, in whom early studies showed Cx40 to be several-fold more abundant in fetal hearts compared with pediatric or adult hearts (Chen et al., 1994). Recent work using samples from humans has indicated that normal atrial conductance requires similar levels of expression of Cx40 and Cx43 (Gemel et al., 2014). Studies in patients with atrial fibrillation indicate decreased expression of Cx40 and the ion channel KCNA5 in atrial myocytes. This possible connection between structure and electrophysiology of atrial fibrillation has been extended into an examination of genetic variants of Cx40 and Cx43 (Zhang et al., 2017; Carballo et al., 2018). Cx40 is also expressed preferentially in the vascular endothelium of human coronary arteries and rat ventricular vascular endothelium (Bastide et al., 1993; Chen et al., 1994). Connexin 45 is reported to be widely but not highly expressed in the human, dog, rabbit, mouse, and rat heart, possibly helping to define the developing conduction system (Kanter et al., 1993; Coppen et al., 1998, 1999; Kim et al., 2016). In vitro work in a rat liver epithelial cell line suggests that expression of Cx43 with coexpression of inducible levels of Cx45 may modulate the size of the gap junction, a feature of importance across age groups (Grikscheit et al., 2008).

Recently, Cx26 mRNA and protein were found to be expressed in the rat, pig, and human cardiomyocytes. The protein was described in the cardiomyocytes of human atrium, rat atrium and ventricle, and the left ventricle of the pig. Unlike other cardiac connexins, these authors described the protein distribution as not at the intercalated disks but as distributed in the cytoplasm at the level of the mitochondria, myofibrils, and cytoplasmic vesicles (Moscati et al., 2018).

Various studies have shown that remodeling of connexin expression and gap junction organization occurs in adult heart conditions such as arrhythmia, ischemic heart disease, and sudden cardiac death (Severs et al., 2008; Molina et al., 2018; Visonà et al., 2018). Alterations can occur in the distribution, amount, and type of connexin expression during different types of heart disease in humans. Pharmacologic modulation of connexins has been proposed as a possible therapy for arrhythmias in patients with ischemic heart disease (De Vuyst et al., 2011). The therapeutic possibilities of cardiac connexins have been considered in a proposal for a modernization of the Vaughan-Williams classification of antiarrhythmic drugs. A new category of drugs acting on connexin-associated channels was suggested for several reasons, supported by investigations with agents that block or open the Cx channels, carbamazepine and the peptide analog rotigaptide (ZP-123), respectively. The authors noted also the changes in gap junction that can accompany alterations in other action potential modifiers, such as remodeling, exemplified by fibrotic change. Changes in Cx43 expression were noted to occur in both dilated and hypertrophic cardiomyopathy (Lei et al., 2018).

**Pannexins.** Pannexins (PANx) are a protein family with three members identified to date (PANX1, PANX2, Panx3) that have a different functional role from connexins. Based on their similar sequence homology with the invertebrate gap junctions and predicted topology similar to that of the gap junction proteins, it was originally suggested that they may form gap junction-like structures. To date, it has been shown that, unlike the connexin gap junction intercellular channels, pannexin oligomers form large-pore channels that are functional in single plasma membranes but not as intercellular channels in appositional membranes (Sosinsky et al., 2011). When open, they provide a conduction pathway between the cytosol and...
extracellular space. PANX1-triggered ATP release has been associated with pathologic fibrosis in canine cardiomyocytes, sympathetic activation in murine cardiac slices, atrial fibrillation in murine tissue, and possibly other processes (Sridharan et al., 2010; Johansen et al., 2011; Dong et al., 2016; Petric et al., 2016). The PANX channel has been shown to be inhibited by a peptide mimicking a sequence of trovafloxacin, potentially explaining the side effects of this antibiotic (Poon et al., 2014). The role of pannexins in physiologic and pathologic processes is not completely understood.

Transporters

Transporters are given a separate section in this review because of their function in both the absorption and excretion of drugs, xenobiotics, and multiple endogenous compounds (Table 1). The transporters are also involved in homeostatic functions and postnatal development of several organs, including the heart (Koepsell, 2013). Transporters are susceptible to many additional chemicals that can act as low- or high-affinity inhibitors (Koepsell et al., 2007). We briefly list the solute carrier transporters (SLCs) that have been identified in the heart.

The solute carrier family 22A (SLC22A) includes organic anion transporter (OAT) transmembrane proteins, organic cation transporters (OCT), and organic carnitine (zwitterion) transporters (OCTN); all these classes have been identified to varying extents in heart tissues.

### OAT and OAT Polypeptides

The OAT polypeptides (OATPs) and OCTs are widely distributed in tissues throughout the body, including the heart. The OATs and OATPs can transport a range of structurally unrelated compounds, including endogenous substances such as thyroid hormone, steroid conjugates, and xenobiotics. OATPs transport mainly large, hydrophobic organic anions, whereas OCTs transport smaller and more hydrophilic anions. Despite the name, OATPs can transport both cationic and neutral compounds (Hagenbuch and Meier, 2003; Roth et al., 2012).

Expression of OATP4A1 mRNA is found throughout the human body, including in the adult human heart (Fujiwara et al., 2001). Compared with other OATPs, OATP4A1 has narrower substrate specificity, with estrone 3-sulfate, benzylpenicillin, and thyroid hormone reported as substrates (Tamai et al., 2000).

Messenger RNA for OATP2A1, originally identified as the prostaglandin transporter, is expressed in the adult human heart, as well as in numerous other tissues (Lu et al., 1996). The activity of this transporter is needed for terminating prostaglandin signaling via prostaglandin receptors. OATP2A1 can also function as an organic anion exchanger (Obaidat et al., 2012). SLCO2A1 has been identified in the pig heart (Van Poucke et al., 2009). Kamo et al. (2017) examined the effects of 636 Food and Drug Administration–approved drugs on OATP2A1 transport activity using human embryonic kidney cells (HEK293) cells expressing OATP2A1. The activity of OATP2A1 was strongly inhibited by 51 approved drugs and stimulated by 10. Inhibitors included suramin, pranlukast, olmesartan, zafirlukast, and losartan, all with IC50 (inhibitor concentration where the response or binding is reduced by half) values less than 2 μM. Although it is difficult to speculate the specific clinical consequences of inhibiting or stimulating the activity of any of these receptors, it is not unreasonable to assume an effect of organ-specific impact.

OATP2B1 protein expression has been described in healthy human atria and ventricles and hearts with dilated and ischemic cardiomyopathy (Grube et al., 2006). Messenger RNA expression was found in all samples and localized to the vascular endothelium. Samples from those treated with atorvastatin exhibited decreased OATP2B1 compared with those that had not taken the medication. Other xenobiotics,

### Table 1

<table>
<thead>
<tr>
<th>Class</th>
<th>Gene</th>
<th>Protein</th>
<th>Localization</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>OAT polyopeptides</td>
<td>OATP4A1</td>
<td>SLCO4A1</td>
<td>N/A</td>
<td>Increased uptake of quinidine, pyrilamine, mitoxantrone.</td>
</tr>
<tr>
<td></td>
<td>OATP2A1</td>
<td>SLCO2A1</td>
<td>N/A</td>
<td>Decreased expression after atorvastatin treatment. Inhibited by multiple FDA-approved drugs.</td>
</tr>
<tr>
<td></td>
<td>OATP2B1</td>
<td>SLCO2B1</td>
<td>N/A</td>
<td>Narrow substrate specificity.</td>
</tr>
<tr>
<td></td>
<td>OATP2B1</td>
<td>SLCO2B1</td>
<td>N/A</td>
<td>Decreased expression during postnatal development.</td>
</tr>
<tr>
<td></td>
<td>OATP2B1</td>
<td>SLCO2B1</td>
<td>N/A</td>
<td>Expression during postnatal development. Narrow substrate specificity.</td>
</tr>
</tbody>
</table>

References

- Tamai et al., 2000;
- Fujiwara et al., 2001;
- Lu et al., 1996; Kamo et al., 2007;
- Atilano-Roque and Joy, 2017;
- Grube et al., 2006; Roth et al., 2012;
- Huber et al., 2007;
- Yabuuchi et al., 1999; Okabe et al., 2008; Nakamura et al., 2010.
including aliskiren, bosentan, and pravastatin, have been demonstrated as substrates for OATP2B (Roth et al., 2012).

OATP3A1 is expressed in the human heart as well as in other organs, including testes, brain, lung, and spleen. Transported substrates include prostaglandin E1, thyroxine, and a nonspecific cyclic oligopeptide endothelin receptor antagonist (Huber et al., 2007). Adult human ventricular cardiomyocytes maintained in culture demonstrated that simvastatin modulated OATP3A1 expression in the cardiomyocytes and HEK293 cells transfected with the OATP3A1 gene. Simvastatin uptake was modulated by the pH of the cultures and the presence of other substrates of the OATP3A1 transporter, suggesting the potential for drug-drug interactions at the level of the heart (Atilano-Roque and Joy, 2017).

OCTs and Organic Carnitine Transporters. OCTs are involved in the cellular uptake of endogenous monoamines (e.g., epinephrine), neurotransmitters (e.g., acetylcholine, serotonin), metabolites (e.g., choline, creatinine), and a variety of drugs (e.g., metformin, cinemidine, farnamidine, prazosin, verapamil). This SLC22 family includes organic carnitine transporters (OCTNs) (reviewed in Koepfell et al. (2007)).

OCTN1 (SLC22A4) expression at the DNA and protein levels has been identified in adult human atria and ventricular surgical samples and is localized to cardiomyocytes. A similar distribution is reported for mouse, rat, and rabbit (Wu et al., 2000; Lamhonwah and Tein, 2006; Iwata et al., 2008; McBride et al., 2009). Coexpression of this transporter in Chinese hamster ovary cells with the human ether-a-go-go-related gene channel potentiated a delayed rectifier K+ channel receptor drug block (McBride et al., 2009). Other investigators have provided data supporting mitochondrial localization of OCTN1 using a variety of transfected human cell lines, as well as mouse hearts (Lamhonwah and Tein, 2006). Drugs that have been demonstrated to be transported by OCTN1 include quinidine, pyrilamine, verapamil, iatropitum, and the chemotherapeutic drugs mitoxantrone and doxorubicin (Yabuuchi et al., 1999; Okabe et al., 2008; Nakamura et al., 2010).

The OCTN2 (SLC22A5) has been identified in mouse (expressed on the plasma membrane), rat, pig, and human (Sekine et al., 1998; Tamai et al., 1998; Iwata et al., 2008; Luo et al., 2014). OCTN2 is expressed in several tissues, including the myocardium (human atria and ventricles), skeletal muscle, renal tubules, and intestine (Gründer et al., 2006). Expression of this transporter is selectively decreased in human cardiomyopathy (Grube et al., 2011). OCTN2 is the primary high-affinity sodium-dependent t-carnitine transporter in humans (Srinivas et al., 2007). t-Carnitine is critically involved in the movement of long-chain fatty acids into the mitochondria for purposes of β-oxidation and removal of fatty acyl-coenzyme A metabolites from the mitochondria. The role of carnitine in postnatal development, and by implication the role of OCTN2, was examined in rat pups from postnatal day 4–20. The concentration of t-carnitine in both serum and cardiac tissue increased from postnatal day 4 to postnatal day 20, with increases of 20% and 50% respectively. The expression of cardiac OCTN1 mRNA remained constant except for an increase at postnatal day 8 that was greater than all other time points. Expression of cardiac OCTN2 mRNA increased postnatally by 100%, whereas OCTN3 mRNA was approximately 200% higher at postnatal day 8 than at postnatal day 4 and remained constant thereafter. These increases are also paralleled by increases in t-carnitine acyl transferases and carnitine palmitoyltransferase 1b and 2b mRNA expression (Ling et al., 2012). These results are consistent with the postnatal increase in fatty acid oxidation rates reported for the heart, attributed in part to maturation of mitochondrial systems and increased t-carnitine. Cell culture evaluation of human and rat OCTN2 transporters indicated that the antibiotics cephaloridine and cefepime produced 40%–90% competitive inhibition of carnitine transport, with rat OCTN2 showing somewhat less affinity for the antibiotics than the human transporter (Ganapathy et al., 2000).

Recent genetic analysis has linked a human biallelic variant in the SLC22A5 gene encoding the OCT2 with pediatric cardiomyopathy that is responsive to exogenously administered carnitine (Lahrouchi et al., 2017). Others have found variants of SLC22A17 and SLC22A7 to be predictive markers of anthracycline cardiotoxicity (Visscher et al., 2015).

OCT3 (SLC22A3) cDNA and/or protein has been identified in mouse, rat, and human tissues (Iversen, 1965; Verhaagh et al., 1999; Gründer et al., 2002). This transporter is expressed in the heart as well as skeletal muscle, aorta, and human liver. This transporter is involved in monoamine uptake in the heart, demonstrated in OCT3-null mice (Zwart et al., 2001). When examined in adult human failing and nonfailing hearts, immunostaining showed that OCT3 expression in the left ventricles was localized with endothelial cells and partially colocalized with gap junction protein connexin-43. No difference in OCT3 expression was found between failing and nonfailing hearts (Solbach et al., 2011).

Madin-Darby canine kidney II cells overexpressing the cardiac transporters OCT1, OCT3, OCTN1, and OCTN2 were used to examine the interaction of these transporters with cardiovascular drugs. OCT1 and OCTN1 were each inhibited to 50% or less residual transport activity by 11 of the 21 tested drugs. OCT3 residual transport activity was reduced to 30% or less by nifedipine, propranolol, and verapamil. OCTN2 was essentially unaffected, with transport activity remaining 70% or greater. Drugs tested were amiodarone, atenolol, atorvastatin, atropine, bisoprolol, carvedilol, digoxin, diltiazem, flecainide, iatropitum bromide, lidocaine, metoprolol, molsidomine, nadolol, nifedipine, propafenone, propranolol, sotalol, spironolactone, talinolol, and verapamil (Grube et al., 2011).

Distribution

Distribution may be seen from several different perspectives, such as distribution of a chemical to the heart from the general circulation (distribution to the heart), as well as movement throughout the heart once the endothelial barrier has been crossed (distribution through the heart). Cardiomyocytes communicate and are physically linked by the intercalated disk (ID), a structure unique to the heart. The gap junction component of the ID is involved in the rapid electrical transmission between cells, as well as passage of small molecules. Relatively recently, the interactions of components of the ID have been redescribed as transitional junctions, perinexus, and area compositae (also called composite junctions or connexomes). Myriad affiliated proteins have also been identified (Forbes and Sperelakis, 1985; Vermij et al., 2017). The overall function of the ID is that of communication, providing passage of ions as well as signaling molecules. Little easily accessible information is available about its potential involvement in xenobiotic distribution throughout the heart.

The gap junction provides direct communication between cardiac cells primarily for electrical communication by allowing ions to pass between cells, and thus it helps coordinate depolarization. The passage of ions occurs within the pore of a gap junction that is formed by an assembly of connexin molecules.

The transitional junction is a recently recognized subcellular functional domain of the ID (Bennett et al., 2006). Its location in the ID is where the myofilibrils lead into the adherens junction. It is hypothesized that this domain may allow for direct communication between the ID and contractile apparatus by acting as an anchor point for titin, the largest known protein, described as the third filament system for the sarcomere.
and important in the process of myofibrillogenesis (Bennett et al., 2006; Myhre and Pilgrim, 2014). It has also been proposed that the transitional junction is the site where new sarcomeres are added to the myofibril, providing elongation or growth of the cardiomyocyte during increased cardiac load (Vermij et al., 2017).

The perinexus, another functional region of the intercalated disk, is the area around the plaque of functional gap junctions in which free connexons (connexin hemichannel) interact with zona occludens-1 (ZO-1). The ZO-1 regulates size, number, and localization of the gap junctions, thus suggesting a potential regulatory role in their distribution. Named for its proximity to bordering gap junctions, the perinexus has been described as a microdomain, enriched in connexons, and containing sodium channels Na1.5, Na1.3, several potassium channels (including Ks and Ke), connexin 43, and other protein-protein interactions, suggesting facilitation of distribution to several ion channels. Another role may be in the contribution to electrical coupling between cardiomyocytes and, thus, cardiac conduction (Rhett et al., 2011, 2013; Rhett and Gourdie, 2012).

The adherens junctions (AJs, sometimes called fascia adherens) occur at cell–cell junctions and help to transduce and transmit contractile forces by anchoring myofibrils and connecting actin filaments from adjacent cells (Vermij et al., 2017). As reviewed by Henderson et al. (2017), AJs have a transmembrane component composed of cadherin proteins and a cytoplasmic plaque component comprising catenin proteins. The N-cadherin protein homodimerizes with N-cadherins from adjacent cells, creating points of calcium-dependent intercellular connection.

During development, gap junctions appear at the ID after formation of the adherens junctions. Vreeker et al. (2014) examined the time frame of human postnatal assembly of the adherens junction proteins N-cadherin and ZO-1 and the desmosomal proteins plakoglobin, desmoplakin, and plakophilin-2. They found that these proteins were initially diffuse and located laterally and then were localized to the ID at approximately 1 year after birth. They also reported the detection of the Na1.5 channel in the ID at 2 years after birth and the connexin 43 protein at 7 years after birth in humans, consistent with the findings of other investigators.

The area composita or adhesion junction is a term proposed by Borrmann et al. (1999) and Franke et al. (2006). An intriguing feature of the area composita and the ID region overall is the relatively prolonged period of postnatal maturation consistently found in rats, dogs, and humans (Pieperhoff and Franke, 2007). In rats, gap junctions, as determined by the location of connexin 43, and adherens junctions, as determined by the locations of desmoplakin and N-cadherin, went from a dispersed distribution across myocyte cell membranes at birth to a polarized distribution at the cell termini, that is, the developing intercalated disks, by postnatal day 20. From postnatal day 20 to postnatal day 90, the gap junctions became progressively concentrated in these zones. Similar findings have been reported for 1- and 3-month-old dogs. The progression of the process in 3-month-old dogs was similar to that in a 20-day-old rat (Angst et al., 1997).

A study of material obtained from pediatric surgical patients aged from 4 weeks to 15 years showed the neonatal human to have a multifocal distribution of connexin 43 gap junctions over the entire surface of the ventricular myocytes. With increasing age, the distribution of the gap junctions became localized to the IDs, reaching an adult pattern by approximately 6 years of age (Peters et al., 1994). The similarity of results in humans, rats, and dogs suggests that this change in the distribution and organization of gap junctions and cellular adhesion is an important process in cardiac maturation (Angst et al., 1997). Within the muscle fibers of the heart, most desmosomes and adherens junctions integrate into composite junctions; however, in the conduction fibers, there is less integration of these two components. A study of Purkinje fibers indicated the presence of discrete desmosomes, discrete adherens junctions, and composite junctions similar to those of the ID (Pieperhoff et al., 2010).

Once a drug moves through the blood-vessel wall, it may traverse the cardiomyocytes and the extracellular matrix, depending on the properties of the xenobiotic and intrinsic properties of the developing animal, which may include the proportion of extracellular water to body fat and the maturity of transport mechanisms. In general, a newborn infant has a higher proportion of water as body weight (70%–75%) compared with an adult (50%–55%), approximately 5% less fat tissue, and 25% less muscle tissue. These relative differences in body composition will affect the volume of distribution of drugs that are distributed within these tissues (Koren, 1997).

Distribution of drugs to the heart will be, in part, due to the movement of the blood, contact with the endothelium, residence time (or plasma half-life), and the chemical properties of the material. Distribution of a drug is characterized by the ratio of total concentration of compound in the tissue to total concentration of compound in the plasma at steady state (Kp). In a recent review article of the drug distribution based on human samples from cardiac surgeries and forensic medical studies, Kp values for different types of drug were summarized (Tylutki and Polak, 2015). In general, the ratios of drug concentration in pericardial fluid and cardiac tissue to the plasma concentration for antibiotics were below 0.5. For amiodarone, an antiarrhythmic compound, the ratio had a mean value of 23, with the highest concentration demonstrated in cardiac fat,
possibly creating a slow-release depot. On average, the myocardial concentration was 10 times greater than that in the plasma. Similarly, concentrations of digoxin were higher in the myocardium than in the plasma.

Physicochemical attributes of the drug itself must be considered for the distribution phase. Lipophilic drugs and organic bases (e.g., tricyclic antidepressants, digoxin, cocaine) tend to accumulate in the myocardium with high affinity. Intraindividual variation in tissue concentrations from one region of the heart to another has been reported. As this is a developing area, there is reasonable speculation that multiple mechanisms are involved in the distribution of drugs throughout the heart (Tylutki and Polak, 2015).

**Metabolism**

**Phase 1.** Phase 1 metabolism is generally viewed as adding or unmasking a functional group, by oxidation, reduction, or hydrolysis. The main actors in these transformations are the cytochrome P450 (P450) families and the cytosolic aldehyde oxidases.

**P450.** P450 enzymes are recognized as critical agents of xenobiotic metabolism, important for the metabolism of foreign and endogenous compounds. Several P450 isoforms have been identified in the human heart (Table 3). To date, most cardiac P450 exploration has been in adult hearts. Little information was found in the literature for a developmental timeline, or ontogeny, for the cardiac P450s.

**CYP2J2** is a predominant heart isoform that has been determined to be constitutively expressed in the adult human heart, with marked interindividual variation (Wu et al., 1997). Its primary function in the heart is drug metabolism, biosynthesis of epoxyeicosatrienoic acid (EET), and nitrous oxide production by metabolism of NCX-4016, a nitric oxide-releasing aspirin. EETs are endogenous molecules from the metabolism of arachidonic acid (AA), which is important in the regulation of cardiovascular homeostasis. An examination of the mRNA and protein levels in the adult human heart, aorta, and coronary arteries showed that CYP2J2 mRNA is highly variable but present in much greater abundance than either CYP2C8 or CYP2C9. Also, in nondiseased adult human hearts, CYP2J2 protein was identified in cardiomyocytes and endothelium of the cardiac vessels. A number of functional polymorphisms of CYP2J2 have been identified in humans, some of which may be associated with coronary artery disease, where overexpression may be one of several factors that contribute to protection (King et al., 2002; Spiecker et al., 2004; Lee et al., 2005; Aliwarga et al., 2018). Whereas cardiac CYP2J2 is relatively minor compared with hepatic metabolism, CYP2J2 has a significant role in some drugs. One example is doxorubicin. Transgenic mice overexpressing cardiomyocyte-specific human CYP2J2 were administered doxorubicin either for 3 days or chronically for 5 weeks. After the acute treatment, hearts of the transgenic overexpressers showed less doxorubicin-induced cardiomyocyte apoptosis compared with wild-type hearts. After chronic treatment, cardiac function, as assessed by echocardiography, was significantly higher in the transgenic CYP2J2 overexpressers than in wild-type mice. Comparison of the microsomes from the WT and transgenic mice showed faster doxorubicin turnover in the CYP2J2 mice. A selective epoxygenase inhibitor, MS-PPOH, blocked the enhanced metabolism observed in the transgenic mice (Zhang et al., 2009). Little is known about the developmental expression of CYP2J2. One study examined human fetal tissue for expression of CYP2J2 mRNA and found it to be expressed ubiquitously in human fetal liver, heart (n = 5 samples), kidney, lung, intestine, and brain (Gaeddert et al., 2006).

CYP2C9 cardiac isoform is inducible and involved with drug metabolism, biosynthesis of EET, and reactive oxygen species.

---

**TABLE 3**

<table>
<thead>
<tr>
<th>Cytochrome P450 (P450) identified in cardiac tissue</th>
<th>Isozyme</th>
<th>Postnatal Ontogeny</th>
<th>Expression</th>
<th>Postnatal Ontogeny</th>
<th>Function</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>CYP1 CYP1A1</td>
<td>Moderate, Inducible</td>
<td>Exposed in mouse heart starting on E8.5</td>
<td>Drug metabolism, metabolism of AA, CYP1A1 inducers increased heart size in chicken</td>
<td>N/A</td>
<td>Drug metabolism, metabolism of AA, CYP1A1</td>
<td>Chaudhary et al., 2009, 2016; Santes-Palacios et al., 2016</td>
</tr>
<tr>
<td>CYP1A2</td>
<td>Inducible</td>
<td>N/A</td>
<td>AA metabolism, NO metabolism</td>
<td>N/A</td>
<td>Metabolizes steroid hormones, fatty acids</td>
<td>Chaudhary et al., 2009, 2016; Delozier et al., 2007; Zhang et al., 2009; Wu et al., 1996; Delozier et al., 2007; Aspromonte et al., 2014</td>
</tr>
<tr>
<td>CYP2C9</td>
<td>Low, Inducible</td>
<td>N/A</td>
<td>Metabolizes steroid hormones, fatty acids, Biosynthesis of EET, ROS production, drug metabolism</td>
<td>N/A</td>
<td>Drug metabolism</td>
<td>Delozier et al., 2007; Zhang et al., 2009; Ren et al., 2013; Aspromonte et al., 2014</td>
</tr>
<tr>
<td>CYP2C18</td>
<td>Low</td>
<td>N/A</td>
<td>Drug metabolism, drug metabolism</td>
<td>N/A</td>
<td>Drug metabolism</td>
<td>Delozier et al., 2007; Zhang et al., 2009; Ren et al., 2013; Aspromonte et al., 2014</td>
</tr>
<tr>
<td>CYP2C13</td>
<td>Low</td>
<td>N/A</td>
<td>Drug metabolism, drug metabolism</td>
<td>N/A</td>
<td>Drug metabolism</td>
<td>Delozier et al., 2007; Zhang et al., 2009; Ren et al., 2013; Aspromonte et al., 2014</td>
</tr>
<tr>
<td>CYP2D6</td>
<td>Low</td>
<td>N/A</td>
<td>Drug metabolism, metabolism of AA, CYP2D6, metabolism of AA</td>
<td>N/A</td>
<td>Drug metabolism</td>
<td>Delozier et al., 2007; Zhang et al., 2009; Ren et al., 2013; Aspromonte et al., 2014</td>
</tr>
<tr>
<td>CYP2J2</td>
<td>High</td>
<td>Expressed in human fetal heart. Little information on developmental timeline</td>
<td>Predominant P450 in biosynthesis of EETs. Substrates, compete with AA</td>
<td>N/A</td>
<td>Drug metabolism, metabolism of AA, CYP2J2</td>
<td>Delozier et al., 2007; Zhang et al., 2009; Wu et al., 1996; Delozier et al., 2007; Aspromonte et al., 2014</td>
</tr>
<tr>
<td>CYP511</td>
<td>Low</td>
<td>N/A</td>
<td>Drug metabolism, e.g., vanadate, hydroxylation of AA, hydroxylation of AA, hydroxylation of AA, hydroxylation of AA, hydroxylation of AA</td>
<td>N/A</td>
<td>Low-level constitutive expression. Associated with local synthesis of aldosterone, cortisone, deoxycorticosterone, corticosterone.</td>
<td>Delozier et al., 2007; Zhang et al., 2009; Wu et al., 1996; Delozier et al., 2007; Aspromonte et al., 2014</td>
</tr>
</tbody>
</table>

*AA, arachidonic acid; DHA, docosahexanoic acid; EPA, eicosapentaenoic acid; EET, epoxyeicosatrienoic acid; HETE, hydroxyeicosatrienoic acid; NO, not available; NO, nitrous oxide; PFUA, polyunsaturated fatty acids; ROS, reactive oxygen species.*
The opposite roles of the EETs and HETEs suggest that the ratios of mRNA and protein expression levels (Shoieb and El-Kadi, 2018). The proportions of EETs and HETEs within each class may also be important. Further, it appears that the CYP2J2. The S-enantiomer increased CYP4F2 and CYP4F11 mono-oxygenation of eicosapentaenoic acid and docosahexaenoic acid may be involved in the production of 20-HETE. As reviewed by Jamieson (2008), hydroxylases, the CYP4A/F isoforms are involved in 20-hydroxyicosatrienoic acid (HETE) synthesis by AA metabolism. Hydroxylases can convert AA to 16-, 17-, 18-, 19-, 20-HETE, but CYP4A/F converts AA only to 20-HETE. As reviewed by Jamieson et al. (2017), eicosapentaenoic acid and docosahexaenoic acid may compete with arachidonic acid (AA) as substrates for these enzymes. Mono-oxygenation of eicosapentaenoic acid and docosahexaenoic acid leads to the production of putative active metabolites, known as resolvins and protectins, that are involved in the resolution of inflammation. The EETs and HETEs tend to have opposite biological effects. The EETs generally produce vasodilation and angiogenesis, whereas the HETEs in general are associated with vasoconstriction and hypertension (Oni-Orisan et al., 2016). Some in vitro work suggests that individual HETEs have unique properties. The effect of enantiomers of 19-HETE on the AA metabolites produced by cultured rat cardiomyoblast (H9c2) cells and human cardiomyocytes (RL-14) was compared. In rat and human cardiomyocytes, both the 19(R)-HETE and the 19(S)-HETE decreased the levels of several of the midchain HETEs. Neither enantiomer of 19-HETE had significant effects on mRNA or protein for CYP2B6, CYP2C8, or CYP2J2. The S-enantiomer increased CYP4F2 and CYP4F11 mRNA and protein expression levels (Shoieb and El-Kadi, 2018). The opposite roles of the EETs and HETEs suggest that the ratios between the two classes are important. Further, it appears that the proportions of EETs and HETEs within each class may also be important in cardiovascular health or development of pathologies. Once produced by CYP2C or CYP2J, EETs are rapidly hydrolyzed to dihydroxyeicosatrienoic acids by soluble epoxide hydrolase (Jamieson et al., 2017). Several marketed therapeutic agents have been demonstrated to be CYP2J2 substrates, including amiodarone, tamoxifen, terfenadine, and thoridazine (Lafite et al., 2006; Lee et al., 2010). Telmisartan and metoprolol are both capable of selectively inhibiting CYP2J2 (Ren et al., 2013). Whether these xenobiotics affect EET production is not clear due to the complexity of overall regulation (Deng et al., 2010). Another class of substrates for CYP2J2 is ω-3 and ω-6 endocannabinoids, endogenously produced from polyunsaturated fatty acids. The metabolism of endocannabinoids produces endocannabinoid epoxides, reported to be vasodilatory and anti-inflammatory (McDougall et al., 2017). Phytocannabinoids have recently also been shown to be substrates of CYP2J2. The different classes of phytocannabinoids are both competitive and noncompetitive inhibition of the endogenous molecule anandamide (Arnold et al., 2018). Rabbids, nonhuman primates, and dogs are similar to humans in having CYP2J2 member identified within the heart. Polymorphisms of the CYP2J member(s) have been proposed to lead to altered organ function. In the case of polymorphisms associated with cardiovascular disease, the results between studies have not been consistent (Aliwarga et al., 2018). Rats and mice have multiple CYP2J enzymes and pseudogenes. Not all rat enzymes possess epoxide- nase activity (Askari et al., 2013). Characterization of the postnatal functional activity of this group of metabolizing enzymes in the heart of any species was minimal to nonexistent. Recent publications by Aliwarga et al. (2018) and Solanki et al. (2018) provide detailed discussions of the role of CYP2J2 in cardiovascular biology. Dogs express several CYP4A and CYP4F enzymes. CYP4A37, CYP4A38, and CYP4A39 are present in beagle hearts at relatively low expression levels. The amino acid sequences for these three enzymes share >90% identity to one another and are approximately 71% and 78% identical to rat CYP4A1 and human CYP4A1, respectively (Graham et al., 2006). Studies by El-Sherbeni et al. (2013) indicate that CYP4A1, although expressed at a relatively low level, is the major ω-hydroxylase in the rat heart. The HETEs have numerous actions in the heart, including vasoconstriction and interaction with various cardiac ion channels (Aspromonte et al., 2014). Identification of P450 enzymes within the heart suggests the possibility of tissue-specific metabolism, either beneficial or adverse. Modulating the activity of the cardiac P450s, that is, induction or inhibition, is also possible. While the inhibition or induction of CYPs in liver or lungs has received extensive investigation, this area of work for the heart is developing. Mice overexpressing human cardiomyocyte CYP2J2 showed increased metabolism of doxorubicin in conjunction with decreased toxicity (Zhang et al., 2009). Cocaine is another drug that has been demonstrated to induce CYP2J2 mRNA (Wang et al., 2002). Studies by Zordoky et al. (2008) demonstrated isoproterenol induction of CYP1A1, CYP1B1, CYP4A3 and inhibition of CYP2C11 and CYP2E1 in hypertrophied rat hearts. Aldehyde Oxidase. Mammalian aldehyde oxidase (AOX) comprises a group of soluble phase 1 enzymes located in the cytosolic fraction of the cell. AOX has marked interspecies variability of expression that has been associated with profound differences in pharmacokinetics between nonclinical and clinical studies, leading to failure of drug development (Jensen et al., 2017). The highest mRNA for AOX isoforms in human tissues is located in the adrenal gland and liver. Essentially no AOX mRNA was identified in the heart of either healthy mice or humans (Terao et al., 2016). Ghaffari et al. (2012) demonstrated AOX activity in heart tissue from control and rats with diabetes mellitus. The enzymatic activity was localized to the organ but not to a cell type or structure. This is a rapidly expanding area of interest and further species-specific information is likely to be forthcoming. Phase 2. Several enzyme classes constitute the predominant agents of what is referred to as phase 2 metabolism. This has been histori- cally viewed as a hydrophilic enhancement of a CYP-modified molecule; however, some of the phase 2 enzyme classes may conjugate molecules that already have groups, such as hydroxyls, carboxyls, or suitable amines. The major transforming enzymes are transferases: UDP-glucuronosyltransferases (UGT), sulfotransferases (SULTs), N-acetyl transferases (NAT), and glutathione S-transferases (GSTs).
Other transferases also exist, and cumulatively constitute a fair proportion of metabolic events (Jancova et al., 2010). **Uridine 5'-Diphosphoglucuronosyltransferase (UDP-Glucuronosyltransferases, or UGT).** The primary enzymes for glucuronic acid conjugation, UGTs are membrane bound in the endoplasmic reticulum and are similar to sulfotransferases. UGTs are important in the metabolism of both xenobiotics and endogenous compounds such as bilirubin and steroid hormones. To date, more than 22 functional human UGT proteins have been identified, some with broad tissue distribution and others that are tissue specific. In addition to its role in xenobiotic metabolism, UGTs are membrane bound in the endoplasmic reticulum and play a critical role in the synthesis of steroid hormones, playing an important role in endocrinology. The metabolite-bound UGTs are associated with the Golgi apparatus of the cell. Substrates for these isoenzymes include lipids, peptides, and proteins, with sulfonation of the endogenous material causing structural and functional change (Li et al., 2014). The UGT enzymes are unique in significant expression early in life, in contrast to UDP-GST. Sulfotransferase activity has been demonstrated in fetal hepatic cytosol preparations, suggesting a role in early metabolism. Investigations by Alnouti and Klaassen (2006) showed mRNA for Sult1a1, Sult1c1, and Sult1e1 (trace amounts) in the hearts of 8-week-old mice of both sexes. The mRNA for Sult3a1 and Sult5a1 were identified in male mouse hearts only, a phenomenon later characterized as androgen-dependent (Alnouti and Klaassen, 2006, 2011). RNA for SULT1C4 was found in the fetal human heart (Sakakibara et al., 1998) Sult1c1 mRNA expression after birth in humans has not been detected in cardiac tissues to any significant amount, and only trace amounts of mRNA have been detected for Sult2b1. There appears to be somewhat greater expression of SULTs in the hearts of male rats. Sex-related expression and distribution of SULT mRNA have been described for Sprague-Dawley rats. Messenger RNA for SULT1A1, as well as trace amounts of SULT1E2, was identified in the hearts of male rats. No mRNA for SULTs was identified in female rats (Dunn and Klaassen, 1998). Piglets lack or show poor sulfonation compared with other species. Minimal evaluation of porcine cardiac phase 2 metabolism is described in the published literature (Helke and Swindle, 2013). Mueller et al. (2015) raise an interesting consideration in the active transmembrane transport needed for cellular influx of hydrophilic substances.

**Sulfotransferases.** Cytosolic SULTs are involved in the sulfonation of xenobiotics and endobiotics such as steroids, bile acids, and thyroid hormones, playing an important role in endocrinology. The membrane-bound UGTs are associated with the Golgi apparatus of the cell. Substrates for these isoenzymes include lipids, peptides, and proteins, with sulfonation of the endogenous material causing structural and functional change (Li et al., 2014). The UGT enzymes are unique in significant expression early in life, in contrast to UDP-GST. Sulfotransferase activity has been demonstrated in fetal hepatic cytosol preparations, suggesting a role in early metabolism. Investigations by Alnouti and Klaassen (2006) showed mRNA for Sult1a1, Sult1c1, and Sult1e1 (trace amounts) in the hearts of 8-week-old mice of both sexes. The mRNA for Sult3a1 and Sult5a1 were identified in male mouse hearts only, a phenomenon later characterized as androgen-dependent (Alnouti and Klaassen, 2006, 2011). RNA for SULT1C4 was found in the fetal human heart (Sakakibara et al., 1998) Sult1c1 mRNA expression after birth in humans has not been detected in cardiac tissues to any significant amount, and only trace amounts of mRNA have been detected for Sult2b1. There appears to be somewhat greater expression of SULTs in the hearts of male rats. Sex-related expression and distribution of SULT mRNA have been described for Sprague-Dawley rats. Messenger RNA for SULT1A1, as well as trace amounts of SULT1E2, was identified in the hearts of male rats. No mRNA for SULTs was identified in female rats (Dunn and Klaassen, 1998). Piglets lack or show poor sulfonation compared with other species. Minimal evaluation of porcine cardiac phase 2 metabolism is described in the published literature (Helke and Swindle, 2013). Mueller et al. (2015) raise an interesting consideration in the active transmembrane transport needed for cellular influx of hydrophilic substances.

### Table 4

<table>
<thead>
<tr>
<th>Component</th>
<th>Reference(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Connexins</td>
<td>Cx26, Cx33, Cx40, Cx45</td>
</tr>
<tr>
<td>OCTN</td>
<td>mRNA for 4A1, 2A1 protein for 2B1, 3A1</td>
</tr>
<tr>
<td>OCT</td>
<td>Protein for OCTN, OCTN2</td>
</tr>
<tr>
<td>OCT</td>
<td>Protein for OCT3</td>
</tr>
<tr>
<td>Area composita</td>
<td>Prolonged development after birth</td>
</tr>
<tr>
<td>ID</td>
<td></td>
</tr>
<tr>
<td>Sulotransferases</td>
<td>mRNA SULT1C4, SULT 2B1</td>
</tr>
<tr>
<td>P450</td>
<td>mRNA and protein 2C8, 2C9, 2J1, 11B2, 4A, 4F</td>
</tr>
<tr>
<td>ABC transporters</td>
<td>mRNA and protein P-glycoprotein, MRPS, ABC9</td>
</tr>
<tr>
<td>Glucose-related</td>
<td>Protein GLUT1, 4, 3, 4, 10, 11, 12 and SGLT1</td>
</tr>
</tbody>
</table>

### Table 5

<table>
<thead>
<tr>
<th>Component</th>
<th>Reference(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Connexins</td>
<td>Cx26, Cx33, Cx40, Cx45</td>
</tr>
<tr>
<td>OCTN</td>
<td>Protein for OCTN, OCTN2</td>
</tr>
<tr>
<td>OCT</td>
<td>Protein for OCT3</td>
</tr>
<tr>
<td>Area composita</td>
<td>Prolonged development after birth</td>
</tr>
<tr>
<td>ID</td>
<td></td>
</tr>
<tr>
<td>Sulotransferases</td>
<td>mRNA SULT1A1, SULT1E2, male rats only</td>
</tr>
<tr>
<td>P450</td>
<td>mRNA 2J2, 2C11, 2E1, 4F, 11B2, 2B6, 2C8, 4A1</td>
</tr>
<tr>
<td>Glucose-related</td>
<td>Protein GLUT1, 4, 3, 4, 10, 11, 12 and SGLT1</td>
</tr>
<tr>
<td>NAT</td>
<td>cDNA for NAT1 and NAT2 mRNA NAT1, NAT2, NAT3</td>
</tr>
</tbody>
</table>

UDP-GT: Uridine 5'-Diphosphoglucone-Transferase; NAT: N-acetyltransferase; OCT: organic cation transporter; OCTN, organic carnitine transporter; P450, cytochrome P450; SULT, sulfotransferase.
sulfated steroids. The SLCO and SLC22A superfamilies of SLC transporters have members associated with sulfated steroid transport. To date, there is a paucity of information concerning the relationship or lack thereof of the SULTs and SLC22A in the heart. The multidrug resistance protein (MRP) has been associated with tissue expression of OATP and MRP relates to total intracellular concentrations of steroids, suggesting a partnering effect of metabolic and transport systems. Overall regulation in general and lar concentrations of steroids, suggesting a partnering effect of metabolic and transport systems. Overall regulation in general and

TABLE 6
Metabolic components identified in mouse heart

<table>
<thead>
<tr>
<th>Component</th>
<th>Reference(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Connexins</td>
<td>Cx43, Cx40, Cx45</td>
</tr>
<tr>
<td>OCTN</td>
<td>Protein for OCTN1, OCTN2</td>
</tr>
<tr>
<td>OCT</td>
<td>cDNA for OCT3</td>
</tr>
<tr>
<td>Sulfotransferases</td>
<td>mRNA Sult1a1, Sult1c1, Sult1e1 mRNA Sult3a1, Sult5a1 in males only</td>
</tr>
<tr>
<td>P450</td>
<td>mRNA 2J2, 4A</td>
</tr>
<tr>
<td>Glucose-related</td>
<td>Protein GLUT1, GLUT2, GLUT3, GLUT8, GLUT10, GLUT12</td>
</tr>
<tr>
<td>UDP-glucuronosyl transferases</td>
<td>mRNA Ugt1a2, Ugt2b5, male mice only</td>
</tr>
<tr>
<td>ABC transporters</td>
<td>ABC9</td>
</tr>
</tbody>
</table>

ABC, ATP-binding cassette; GLUT, facilitative glucose transporter; OCT, organic cation transporter; OCTN, organic carnitine transporter; P450, cytochrome P450; SULT, sulfotransferase.

TABLE 7
Metabolic components identified in canine heart

<table>
<thead>
<tr>
<th>Component</th>
<th>Reference(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Connexins</td>
<td>Cx45</td>
</tr>
<tr>
<td>Area composita and ID</td>
<td>Prolonged development after birth</td>
</tr>
<tr>
<td>P450</td>
<td>CYP4A, 4F, 4A37, 4A38, 4A39</td>
</tr>
<tr>
<td>Glucose related</td>
<td>GLUT4</td>
</tr>
</tbody>
</table>

ID, intercalated disk; P450, cytochrome P450.

Excretion

**ATP Binding Cassette Superfamily of Transport Proteins.** ATP-binding cassette (ABC) transporters, which use energy from ATP hydrolysis to move substances against chemical or electrical gradients, is one of the largest transporter superfamilies (Table 2). Several ABC transporters, such as ABCB1 (P-glycoprotein), ABCG5 (MRP5), or ABCG9 (SUR2), are present in the human heart (Solbach et al., 2006). These transporters are involved in lipid metabolism and movement, as well as cardiomocyte function via cyclic nucleotide efflux and metabolism, homeostasis, and potentially xenobiotic movement (Ichikawa et al., 2012; Schumacher and Benndorf, 2017).

One of the best characterized ABC transporters is P-glycoprotein, also known as P-gp or multidrug resistance protein 1 (MDR1), the product of ABCB1 gene. P-gp is a drug efflux pump to protect the organism against toxic xenobiotic compounds. In the human heart, P-gp has been identified at both the mRNA and protein levels in endothelial cells of cardiac arterioles and capillaries. P-gp expression was greatly reduced in samples from dilated cardiomyopathy hearts (Meissner et al., 2002). Variable P-gp expressions were reported from human heart tissues (Meissner et al., 2004). Digoxin has been demonstrated to be a substrate for P-gp, as well as the β-adrenergic antagonists talinolol and celiprolol (Karlsson et al., 1993; Westphal et al., 2000). Overexpression of P-gp has also been associated with multiple drug resistance, as well as decreased cytotoxicity of agents such as anthracycline chemotherapeutics (Krisha and Mayer, 2000; Zhou et al., 2016). Individual variability of expression of this transporter is a possible explanation for variable response to substrates.

The multidrug resistance protein 5 (MRP5/ABCC5) has been localized to the heart, in terms of both mRNA and protein expression. Using samples from adult humans presenting either for bypass surgery or transplantation, MRP5 was identified in three different cardiac cell types: vascular smooth muscle cells, cardiomocytes, and vascular endothelial cells. MRP5 mediates the cellular efflux of 3’,5’-cyclic nucleotides, cAMP, and cGMP. Therefore, it is suggested that MRP5 can affect NO/cGMP signaling by reducing its intracellular content in addition to its metabolic degradation by phosphodiesterases. Greater expression of MRP5 was observed in the ischemic cardiomyopathy...
tissues compared with the normal ventricular samples (Dazert et al., 2003).

In addition to chemical excretion, ABC transporters also play important roles in heart development, including the shift from fetal glycolytic to postnatal mitochondrial oxidative metabolism. For example, SUR2 (encoded by ABCC9) is a regulatory subunit of the major potassium-sensitive ATP (K$_{ATP}$) channel in the heart. SUR2-containing K$_{ATP}$ channels are enriched in the sarcolemma, where they control opening or closing of the potassium channel in response to the intracellular energy state. When Abcc9, the gene coding for ABCC9, is deleted from mice, the period from postnatal day 2 to postnatal day 8 is marked by a failure to develop adequate mitochondrial networks to support cardiac growth. These animals develop a fatal neonatal cardiomyopathy (Fahrenbach et al., 2014).

**Energy Metabolism**

Continuous work means the heart requires a continuous energy supply. It is estimated that approximately 60%–70% of the ATP generated in the heart is consumed in contraction, and the remaining 30%–40% is consumed by the sarcoendoplasmic reticulum calcium transport ATPase and other ion pumps (Schramm et al., 1994; Stanley et al., 2005). The profound energy demand makes this aspect of cardiac metabolism one where even small disruptions or alterations may have significant consequences. This is also an area of intense study for the connection to heart failure and cardiomyopathies.

The mammalian fetal heart generates most of its ATP from glycolysis and lactate oxidation. In the newborn human, almost half of total ATP is produced from glycolysis. In the mature human heart, glucose generates approximately 25%–30% of total energy. The postnatal energy transition is from glucose metabolism to fatty acids and mitochondrial oxidative metabolism (reviewed in Onay-Besikci (2006)). The time frame of this transition is described for several species. Early work by Breuer et al. (1967, 1968) suggested that from 7 to 12 days after birth and from 13 to 21 days after birth, dogs had different cardiac metabolic profiles from each other and from adult dogs, based on determination of glucose, lactate, and pyruvate from coronary arterial and venous blood flow (Breuer et al., 1967). Follow-up studies on puppies from 7 to 13 days of age and a second group from 13 to 28 days of age suggested that the change from use of carbohydrates to use of fatty acids occurs at approximately the 14th day of life in dogs. Also, in the third week of life, the heart changed from lactate release to lactate uptake, coinciding with the beginning of free fatty acid uptake (Breuer et al., 1968). In rabbits, the contribution of glycolysis decreases from 44% on day 1 to approximately 10% of total cardiac ATP by day 7 after birth, similar to production in an adult human heart (Lopaschuk et al., 1991). Consistent with the decrease in glycolysis, isolated rabbit heart preparations demonstrated fatty acids as the main source of energy by 2 weeks of age (Itoi and Lopaschuk, 1993). Newborn rabbits with volume overload–induced hypertrophy had fatty acid oxidation rates 60% lower than control animals, and glycolysis rates increased by 246% (P < 0.05). Overall, ATP production was significantly lower in the hypertrophied rabbit hearts (Oka et al., 2012).

Growing/proliferating cells are usually characterized by immaturity of both the mitochondria and the mitochondrial networks (Lopaschuk and Jaswal, 2010; Tuomainen and Tavi, 2017). The endogenous metabolic development of the heart after birth includes a surge of mitochondrial biogenesis, followed by mitochondrial maturation, redistribution, and packing of mature mitochondria along myofibrils. This stage of maturation includes increases in the processes of mitophagy (selective autophagous degradation of mitochondria), fusion, and fission (Dorn et al., 2015). Ultimately, postnatal development of cardiac energy production depends on mitochondrial maturation, with a complex interrelationship with the cardiac EETs (Singh et al., 2016).

Another aspect of cardiac energy metabolism is the availability of substrate. Two classes of glucose transporters have been identified in the human heart: GLUTs (facilitative glucose transporters) and SGLTs (sodium-glucose cotransporters) (reviewed in Szablewski (2017)). GLUT1 and GLUT4 have been identified in the rat heart. During fetal life of rats, GLUT1 (encoded by SLC2A1 and a member of the major facilitator superfamily) and hexokinase I are the predominant glucose transporters present in rat hearts. Soon after birth in the rat, cardiac GLUT1/hexokinase I expression decreased, whereas after postnatal day 10, GLUT4 and hexokinase II expression increased (Wang and Hu, 1991; Santalucia et al., 1992). The insulin-sensitive GLUT4 represents 70% of the glucose transporters in an adult human heart, with GLUT1 the next most prominent transporter. In resting (low insulin) conditions, GLUT4 is located primarily in intracellular membrane compartments. Stimuli such as ischemia, catecholamines, or insulin will cause acute translocation of GLUT4 to the cell surface, without transcription or translation, increasing glucose transport into cardiomyocytes by as much as 10- to 20-fold, as demonstrated in isolated rat cardiomyocytes, hearts of diabetic swine, and nondiabetic dogs (Stanley et al., 1994; Fischer et al., 1996; Brosius et al., 1997a; Young et al., 1997; Mueckler and Thorens, 2013). Expression of GLUT4 is also influenced by fatty acids and thyroid hormone (Gosteli-Peter et al., 1996; Fink et al., 2002). A study in adult dogs indicated a greater protein distribution of GLUT4 in atria compared with ventricles. During chronic heart failure in dogs induced by pacing, GLUT4 protein content was highest in the left ventricle while the amount in the right atrium was decreased (Ware et al., 2011).

GLUTs 3, 8, 10, 11, and 12 have also been identified in the adult human heart; however, characterization of their physiologic roles is incomplete. Transcriptional regulation has been determined to be the main mechanism for expression and activity of these molecules in the heart. GLUT1 in an adult may account for up to 40% of glucose transport, regulated by chronic hypoxia and long-term fasting (Kraegen et al., 1993; Brosius et al., 1997b). GLUT3 has been identified in both fetal and adult human hearts (Kayano et al., 1988; Grover-McKay et al., 1999). The function of GLUT8 is unclear, but it has been identified in the mouse heart, along with lower levels of GLUT3, GLUT10, and GLUT12. Studies in paced mice given a long-term high-fat diet suggest a role in regulating atrial activity (Aerni-Flesner et al., 2012; Maria et al., 2018). GLUT1 transports both glucose and fructose. This transporter has three splice variants, differentially expressed in heart, skeletal muscle, kidney, adipose tissue, and pancreas (Doee et al., 2001; Scheepers et al., 2005). GLUT10 (SLC2A10) also has wide tissue distribution beyond the heart. Homozygous mutation of the SLC2A10 gene is linked to a disorder called arterial tortuosity syndrome, in which morphologic abnormalities of the arteries are present. Like other GLUTs, GLUT12 is present in heart and skeletal muscle, as well as prostate and small intestine. In healthy and diabetic mouse hearts, no difference was seen in total GLUT12. Under the conditions of this study, GLUT12 translocation did not appear to be insulin-responsive, unlike GLUT4 (Waller et al., 2013).

The SGLT exists in several isoforms. The SGLT1 isomorph is expressed in the small intestine, renal proximal tubule, and heart (Turk et al., 1991; Zhou et al., 2003). The SGLT1 was expressed in healthy human and murine myocardial tissue and significantly
upregulated in diabetes mellitus, ischemia, and hypertrophy (Banerjee et al., 2009; Di Franco et al., 2017).

Discussion and Conclusion

The heart contains metabolic machinery for processing endogenous material for energy production, physiologic development, and homeostasis. The same machinery can also transport and process xenobiotics. The mitochondrial and nuclear regulation of these pathways is intricately connected and incompletely understood. The intricacy of metabolic machinery is made more complex when genetic variants of the components are considered. We found little information about the postnatal development of cardiac metabolism, exception for energy processes. Other than energy metabolism, little information was found about ontology, time to full or mature function, and species differences. The last data gap is not surprising as much of the current information has been generated in human tissues. The limitation to this is that most of these human studies have had small sample sizes and tend to be from mature or aged hearts. The data from nonhuman species included some information about development of metabolic machinery for energy production but leave gaps primarily for transporters, phase 1, and phase 2 metabolism.

The relatively new concept of protein partners for coordination and communication of effects of receptors and transporters between distant sites is an intriguing one. Conceptually, it fits with an emerging systems biology view of receptors and transporters having roles in metabolite signaling pathways, interorgan communication, as well as neuroendocrine, growth factor, and general homeostatic processes (Nigam, 2018), and links development of local metabolic capability with the regulation of protein isoform shifts. The signaling pathways for both these phenomena, as well as the potential connections between the two, are incompletely described.

A detailed understanding of cross-species cardiac metabolism offers several possibilities (Tables 4, 5, 6, and 7). First, it may be possible to leverage local metabolic capabilities to create location-specific conversions of prodrugs to active moieties. Second, an understanding of the natural progression of ontogeny, followed by mature function and then physiologic deterioration, may assist in understanding the differences in drug effects between adults and children in general and special disease populations within age groups. With greater understanding of species similarities both in composition and ontology, it may be possible to design more informative nonclinical studies.

It seems intuitive that there may be developmental periods sensitive to xenobiotic perturbation or pathways susceptible at any age to chemical disruption. Although some information is available about pharmaceuticals that were substrates or inhibitors for cardiac enzymes or transporters, little characterization of downstream effects or effects on signaling pathways was found, which has relevance for pediatric therapeutics: disruption of normal developmental pathways. Effects on signaling pathways was found, which has relevance for pediatric therapeutics. Effects on signaling pathways, interorgan communication, as well as neuroendocrine, growth factor, and general homeostatic processes (Nigam, 2018), and links development of local metabolic capability with the regulation of protein isoform shifts. The signaling pathways for both these phenomena, as well as the potential connections between the two, are incompletely described.

A detailed understanding of cross-species cardiac metabolism offers several possibilities (Tables 4, 5, 6, and 7). First, it may be possible to leverage local metabolic capabilities to create location-specific conversions of prodrugs to active moieties. Second, an understanding of the natural progression of ontogeny, followed by mature function and then physiologic deterioration, may assist in understanding the differences in drug effects between adults and children in general and special disease populations within age groups. With greater understanding of species similarities both in composition and ontology, it may be possible to design more informative nonclinical studies.

It seems intuitive that there may be developmental periods sensitive to xenobiotic perturbation or pathways susceptible at any age to chemical disruption. Although some information is available about pharmaceuticals that were substrates or inhibitors for cardiac enzymes or transporters, little characterization of downstream effects or effects on signaling pathways was found, which has relevance for pediatric therapeutics: disruption of normal developmental pathways. Effects on cardiac function, reaching full adult cardiovascular capacity, or increased susceptibility to different forms of cardiovascular disease may not be perceptible for years to decades after exposure to a drug. By that time, many confounding factors have entered the picture. The same information about downstream effects on signaling pathways may also be informative for conditions such as heart failure. Events and signaling pathways unique to different ages (e.g., adult or geriatric) or physiologic stages may help to identify sensitive developmental windows and, further, to avoid unintended or adverse effects, such as acceleration of naturally occurring cardiovascular disease.

Important areas for further exploration are cardiac metabolism related to drug toxicity, or targeted therapeutics, involvement in normal postnatal development, and modulation of adult homeostasis. We found some descriptions of cardiac-specific metabolism in the literature, but this is clearly an emerging area of research in both therapeutics and toxicity. The possible association of xenobiotic modulation of postnatal development seems to be largely understudied. In this area, greater understanding of postnatal ontogeny becomes an issue of translational significance. Studies using human tissue have produced information for several disease states; however, sample sizes tend to be small, and it is unclear how much the results can be extrapolated to the population in general, given the genetic diversity of humans.

Comparisons of species effects, or translational value, were similarly limited; direct interspecies comparisons are rare. Differences between both species, breeds within species and strains within breeds have been demonstrated. Studying postnatal development in different animal species is already complicated by the brevity of various physiologic windows and, in some cases, lack of similarity of the general developmental stage to the equivalent human developmental stage. Ideally, hypothesis-driven studies could be designed with an understanding of species differences, thus maximizing the translational value of the work. At this time, it is not possible or realistic to make generic recommendations of nonhuman species for investigative work or safety assessment based on the available information. Clearly, understanding the postnatal ontogeny of metabolism overall has the potential to significantly impact the development of pediatric therapeutics.

Acknowledgments

This review is part of an effort of several working groups coordinated by the Health and Environmental Sciences Institute to identify, compile, and integrate information concerning the postnatal development of various body systems, with emphasis on metabolism, the coordinated processes encompassing absorption, distribution, transformation (metabolism), and excretion (De Schaepdirjver et al., 2018). This working group is composed of members from the federal government, industry, and academic communities. This work was supported [in part] by the NIH, National Institute of Environmental Health Sciences.

Authorship Contributions

Wrote or contributed to the writing of the manuscript: Hausner, Elmore, Yang.

References


Address correspondence to: Elizabeth A. Hausner, Division of Cardiovascular and Renal Products, Center for Drug Evaluation and Research, United States Food and Drug Administration, White Oak, Building 22/Room 4168, 10903 New Hampshire Avenue, Silver Spring, MD 20993. E-mail: Elizabeth.Hausner@fda.hhs.gov; or Susan A. Elmore, Toxicologic Pathologist, National Toxicology Program, National Institute of Environmental Sciences, 111 TW Alexander Drive, RTP, NC 27709. E-mail: Elmore@niehs.nih.gov; or Dr. Xi Yang, Division of Cardiovascular and Renal Products CDER/FDA White Oak, Bldg 22/ Room 4175, 10903 New Hampshire Avenue, Silver Spring, MD 20993. E-mail: Xi.Yang@fda.hhs.gov.